| Patent application number | Description | Published |
|---|
| 20090275775 | METHOD FOR PRODUCING ISOCYANATES - The invention relates to a multistage process for the continuous preparation of organic, distillable isocyanates, preferably diisocyanates, particularly preferably aliphatic or cycloaliphatic diisocyanates, by reaction of the corresponding organic amines with urea and alcohols to liberate ammonia and form low molecular weight monomeric urethanes and thermal dissociation of the latter, in which by-products formed are at least partly utilized. | 11-05-2009 |
| 20100274046 | METHOD FOR PRODUCING ISOCYANATES - The present invention relates to a multiple-stage process for the continuous preparation of organic, distillable polyisocyanates, preferably diisocyanates, more preferably aliphatic or cycloaliphatic diisocyanates, by reaction of the corresponding organic poly-amines with ureas to form low-molecular monomeric polyureas, and the thermal decomposition thereof. | 10-28-2010 |
| 20110137067 | METHOD FOR PRODUCING URETHANES COMPOSED OF DI-FUNCTIONAL AROMATIC AMINES AND DIALKYL CARBONATES - A process for preparing urethanes by reacting aromatic diamines with a dialkyl carbonate, wherein the alkyl radical of the organic dialkyl carbonate comprises 2-18 carbon atoms and one or more heteroatoms and the reaction is performed in the presence of a catalyst. | 06-09-2011 |
| Patent application number | Description | Published |
|---|
| 20090018314 | GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS - Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases. | 01-15-2009 |
| 20090061511 | GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS - Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases. | 03-05-2009 |
| 20090069553 | GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS - Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases. | 03-12-2009 |
